DaVita Inc
DVA
Get informed when a big investor buys or sells
+ Follow
Current Fair Value
23.9% upsideUndervalued by 23.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $15.21 Billion |
|---|---|
| Enterprise Value | $27.74 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $9.72 |
| Beta | 0.88 |
| Outstanding Shares | 67,390,000 |
Return
| Return on Equity | -103.43% |
|---|---|
| Return on Assets | 4.47% |
| Return on Invested Capital | 12.51% |
Valuation & Multiples
| P/E Ratio | 23.35 |
|---|---|
| PEG | 109.89 |
| Price to Sales | 1.14 |
| Price to Book Ratio | 15.62 |
| Enterprise Value to Revenue | 2.01 |
| Enterprise Value to EBIT | 15.16 |
| Enterprise Value to Net Income | 35 |
| Total Debt to Enterprise | 0.48 |
| Debt to Equity | -17.55 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 79.49% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.91%▼ 71.18% |
|---|---|
| Total Invested | $136.92M▼ 98.56% |
| Investors Holding | 87▼ 522.00% |
ESG Score
No data
About DaVita Inc
CEO: Javier Rodriguez Relevant Senate Committees
This is the most powerful committee for DaVita, as it controls taxation, trade, and crucially, Medicare pricing and entitlement spending, which are fundamental to the company's revenue and profitability.
This committee directly allocates federal spending, determining the precise funding levels for Medicare and Medicaid, which are major payers for DaVita's dialysis services.
This committee directly regulates the FDA (influencing medical devices and drugs used in dialysis), and critical labor laws that impact DaVita's significant workforce and operating costs.
Oversight of antitrust laws and the DOJ is highly relevant for a consolidating industry like healthcare, directly impacting DaVita's potential M&A activities and market structure.